Effects of Δ9-THC on VIP-induced prolactin secretion in anterior pituitary cultures: Evidence for the presence of functional cannabinoid CB1 receptors in pituitary cells

Fernando Rodríguez De Fonseca, T. Wenger, Miguel Navarro, Laura L. Murphy

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Peripheral administration of cannabinoid CB1 receptor agonists to laboratory rats induce a brief rise in plasma prolactin (PRL) levels followed by a prolonged decrease in PRL secretion from the pituitary. While the inhibitory component of this biphasic response depends on the cannabinoid- induced activation of dopamine release from hypothalamic terminals located in the median eminence, the neurobiological mechanisms underlying the activation phase of PRL release remains to be explained. In the present study the possible direct effect of the cannabinoid receptor agonist Δ9- Tetrahydrocannabinol (THC) on prolactin secretion and cAMP accumulation was examined in anterior pituitary cultures. THC (0.1 and 1 μM) increased cAMP levels, and induced PRL release (1 and 10 λ). THC did not affect vasoactive intestinal peptide (VIP, 0.5 μM) induced cAMP accumulation in pituitary cultures, showing additive effects at THC 1 μM concentration. However, THC did prevent VIP-dependent increases in prolactin secretion. These results indicate that THC, through a direct pituitary action, activates both the synthesis of cAMP and PRL release and interferes with intracellular mechanisms involved in PRL secretion by VIP. These actions could be mediated through cannabinoid CB1 receptors which were found to be present in anterior pituitary cells, including lactotrophs, as revealed by immunocytochemistry with a specific polyclonal antibody raised against the CB1 receptor protein.

Original languageEnglish
Pages (from-to)114-122
Number of pages9
JournalBrain Research
Volume841
Issue number1-2
DOIs
Publication statusPublished - Sep 11 1999

Fingerprint

Cannabinoid Receptor CB1
Dronabinol
Prolactin
Cannabinoid Receptor Agonists
Lactotrophs
Median Eminence
Cannabinoids
Vasoactive Intestinal Peptide
Dopamine
Immunohistochemistry
Antibodies

Keywords

  • CAMP
  • Cannabinoid
  • CB receptor
  • Lactotroph
  • Pituitary
  • Prolactin
  • Rat
  • Vasoactive intestinal peptide (VIP)

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

Effects of Δ9-THC on VIP-induced prolactin secretion in anterior pituitary cultures : Evidence for the presence of functional cannabinoid CB1 receptors in pituitary cells. / Rodríguez De Fonseca, Fernando; Wenger, T.; Navarro, Miguel; Murphy, Laura L.

In: Brain Research, Vol. 841, No. 1-2, 11.09.1999, p. 114-122.

Research output: Contribution to journalArticle

@article{87e02bb1727e4618bb3396057dd5b86c,
title = "Effects of Δ9-THC on VIP-induced prolactin secretion in anterior pituitary cultures: Evidence for the presence of functional cannabinoid CB1 receptors in pituitary cells",
abstract = "Peripheral administration of cannabinoid CB1 receptor agonists to laboratory rats induce a brief rise in plasma prolactin (PRL) levels followed by a prolonged decrease in PRL secretion from the pituitary. While the inhibitory component of this biphasic response depends on the cannabinoid- induced activation of dopamine release from hypothalamic terminals located in the median eminence, the neurobiological mechanisms underlying the activation phase of PRL release remains to be explained. In the present study the possible direct effect of the cannabinoid receptor agonist Δ9- Tetrahydrocannabinol (THC) on prolactin secretion and cAMP accumulation was examined in anterior pituitary cultures. THC (0.1 and 1 μM) increased cAMP levels, and induced PRL release (1 and 10 λ). THC did not affect vasoactive intestinal peptide (VIP, 0.5 μM) induced cAMP accumulation in pituitary cultures, showing additive effects at THC 1 μM concentration. However, THC did prevent VIP-dependent increases in prolactin secretion. These results indicate that THC, through a direct pituitary action, activates both the synthesis of cAMP and PRL release and interferes with intracellular mechanisms involved in PRL secretion by VIP. These actions could be mediated through cannabinoid CB1 receptors which were found to be present in anterior pituitary cells, including lactotrophs, as revealed by immunocytochemistry with a specific polyclonal antibody raised against the CB1 receptor protein.",
keywords = "CAMP, Cannabinoid, CB receptor, Lactotroph, Pituitary, Prolactin, Rat, Vasoactive intestinal peptide (VIP)",
author = "{Rodr{\'i}guez De Fonseca}, Fernando and T. Wenger and Miguel Navarro and Murphy, {Laura L.}",
year = "1999",
month = "9",
day = "11",
doi = "10.1016/S0006-8993(99)01809-0",
language = "English",
volume = "841",
pages = "114--122",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Effects of Δ9-THC on VIP-induced prolactin secretion in anterior pituitary cultures

T2 - Evidence for the presence of functional cannabinoid CB1 receptors in pituitary cells

AU - Rodríguez De Fonseca, Fernando

AU - Wenger, T.

AU - Navarro, Miguel

AU - Murphy, Laura L.

PY - 1999/9/11

Y1 - 1999/9/11

N2 - Peripheral administration of cannabinoid CB1 receptor agonists to laboratory rats induce a brief rise in plasma prolactin (PRL) levels followed by a prolonged decrease in PRL secretion from the pituitary. While the inhibitory component of this biphasic response depends on the cannabinoid- induced activation of dopamine release from hypothalamic terminals located in the median eminence, the neurobiological mechanisms underlying the activation phase of PRL release remains to be explained. In the present study the possible direct effect of the cannabinoid receptor agonist Δ9- Tetrahydrocannabinol (THC) on prolactin secretion and cAMP accumulation was examined in anterior pituitary cultures. THC (0.1 and 1 μM) increased cAMP levels, and induced PRL release (1 and 10 λ). THC did not affect vasoactive intestinal peptide (VIP, 0.5 μM) induced cAMP accumulation in pituitary cultures, showing additive effects at THC 1 μM concentration. However, THC did prevent VIP-dependent increases in prolactin secretion. These results indicate that THC, through a direct pituitary action, activates both the synthesis of cAMP and PRL release and interferes with intracellular mechanisms involved in PRL secretion by VIP. These actions could be mediated through cannabinoid CB1 receptors which were found to be present in anterior pituitary cells, including lactotrophs, as revealed by immunocytochemistry with a specific polyclonal antibody raised against the CB1 receptor protein.

AB - Peripheral administration of cannabinoid CB1 receptor agonists to laboratory rats induce a brief rise in plasma prolactin (PRL) levels followed by a prolonged decrease in PRL secretion from the pituitary. While the inhibitory component of this biphasic response depends on the cannabinoid- induced activation of dopamine release from hypothalamic terminals located in the median eminence, the neurobiological mechanisms underlying the activation phase of PRL release remains to be explained. In the present study the possible direct effect of the cannabinoid receptor agonist Δ9- Tetrahydrocannabinol (THC) on prolactin secretion and cAMP accumulation was examined in anterior pituitary cultures. THC (0.1 and 1 μM) increased cAMP levels, and induced PRL release (1 and 10 λ). THC did not affect vasoactive intestinal peptide (VIP, 0.5 μM) induced cAMP accumulation in pituitary cultures, showing additive effects at THC 1 μM concentration. However, THC did prevent VIP-dependent increases in prolactin secretion. These results indicate that THC, through a direct pituitary action, activates both the synthesis of cAMP and PRL release and interferes with intracellular mechanisms involved in PRL secretion by VIP. These actions could be mediated through cannabinoid CB1 receptors which were found to be present in anterior pituitary cells, including lactotrophs, as revealed by immunocytochemistry with a specific polyclonal antibody raised against the CB1 receptor protein.

KW - CAMP

KW - Cannabinoid

KW - CB receptor

KW - Lactotroph

KW - Pituitary

KW - Prolactin

KW - Rat

KW - Vasoactive intestinal peptide (VIP)

UR - http://www.scopus.com/inward/record.url?scp=0033546837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033546837&partnerID=8YFLogxK

U2 - 10.1016/S0006-8993(99)01809-0

DO - 10.1016/S0006-8993(99)01809-0

M3 - Article

C2 - 10546994

AN - SCOPUS:0033546837

VL - 841

SP - 114

EP - 122

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -